Phentolamine (DB00692): A Comprehensive Pharmacological and Clinical Monograph

Introduction and Overview

Phentolamine is a potent, reversible, non-selective alpha-adrenergic receptor antagonist belonging to the imidazoline class of chemical compounds.[1] Its clinical history represents a compelling narrative of pharmacological evolution and therapeutic repurposing. Initially introduced for the systemic management of hypertension, this application was ultimately curtailed due to a significant burden of cardiovascular and gastrointestinal adverse effects associated with chronic, large oral doses.[1] Despite this early setback, the potent and rapid vasodilatory properties of phentolamine secured its role as a critical, life-saving agent for the management of acute hypertensive emergencies, most notably those arising from the catecholamine excess characteristic of pheochromocytoma.[3]

The therapeutic journey of phentolamine serves as a classic paradigm of drug repurposing in modern medicine. The same powerful systemic effects that proved problematic for chronic therapy have been ingeniously harnessed for niche, localized applications where the benefit-risk profile is exceptionally favorable. This strategic shift is exemplified by the development of two highly successful formulations: OraVerse, an injectable solution for the reversal of soft-tissue anesthesia in dentistry, and Ryzumvi, an ophthalmic solution for the reversal of pharmacologically-induced mydriasis.[2] These innovations have transformed phentolamine from a specialized hospital-based emergency drug into a valuable tool in outpatient and specialty clinic settings.

The entire clinical profile of phentolamine—its efficacy, its characteristic adverse effects, and the trajectory of its therapeutic applications—is dictated by a single, core pharmacological feature: its non-selective antagonism of both α1- and α2-adrenergic receptors. This dual blockade underpins its potent efficacy in states of catecholamine excess, but it is also the direct cause of its most significant side effects, namely profound hypotension and a pronounced reflex tachycardia. This report will provide a comprehensive analysis of phentolamine, examining how this fundamental mechanism of action governs its physicochemical properties, pharmacokinetics, clinical utility, safety profile, and its remarkable evolution within the therapeutic armamentarium.

Identification and Physicochemical Properties

A precise understanding of phentolamine's chemical identity and physical characteristics is foundational to appreciating its pharmacological behavior and formulation development.

Nomenclature and Identifiers

Phentolamine is identified by a variety of chemical names, synonyms, and database identifiers, reflecting its long history and extensive study across chemical, pharmacological, and clinical domains. Its formal International Union of Pure and Applied Chemistry (IUPAC) name is 3-phenol.[2] An alternative systematic name is 2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazoline.[5] Common synonyms used in international literature include Fentolamina, Phentolamin, and Phentolaminum.[5]

Commercially, phentolamine has been marketed under several brand names. The original brand, Regitine, was discontinued in the United States by Novartis in 2000 but remains available in Canada.[9] The modern, repurposed formulations are known as OraVerse for dental use and Ryzumvi for ophthalmic use.[2] The multitude of identifiers across various scientific databases underscores the drug's significance and facilitates cross-referencing for researchers. A consolidated table of these identifiers and key chemical properties provides a crucial tool for unambiguous data retrieval from disparate sources.

Table 1: Phentolamine Identifiers and Chemical Properties

Property	Value	Source(s)
DrugBank ID	DB00692	1
CAS Number	50-60-2 (base)	1
	65-28-1 (mesylate salt)	1
	73-05-2 (hydrochloride salt)	1
UNII	Z468598HBV	1
PubChem CID	5775	1
ChEBI ID	CHEBI:8081	1
KEGG ID	D08362	1
ATC Codes	C04AB01, V03AB36, G04BE05	2
Molecular Formula	C17​H19​N3​O	5
Average Weight	281.3523 g/mol	5
Monoisotopic Weight	281.152812245 g/mol	5

Physicochemical Properties

The physical and chemical properties of phentolamine influence its stability, solubility, formulation, and biological activity.

• Physical Description: Phentolamine base is a solid that forms crystals.[1]
• Melting Point: The melting point varies depending on the specific form of the compound. The base melts in the range of 175–181 °C.[1] Its salts have distinct, higher melting points; for example, phentolamine hydrochloride melts at 239–240 °C.[1]
• Solubility: The free base exhibits low aqueous solubility, measured at 0.272 g/L.[1] To improve solubility for parenteral formulations, it is prepared as a salt, such as the hydrochloride or mesylate salt. Phentolamine hydrochloride is more soluble, with one gram dissolving in 50 mL of water.[1] A critical characteristic for clinical use is the instability of its aqueous solutions, which cannot be stored and must be freshly prepared prior to administration.[1]
• Lipophilicity (LogP): The partition coefficient (LogP) is reported to be 3.3, indicating that phentolamine is a relatively lipophilic molecule.[1] This lipid solubility facilitates its distribution into tissues and is consistent with reports of its ability to cross the blood-brain barrier.[5]
• Acidity/Basicity (pKa): Phentolamine has two key ionizable groups. The pKa of the phenolic hydroxyl group (strongest acidic) is 9.78, while the pKa of the imidazoline ring (strongest basic) is 9.02.[4] At physiological pH (around 7.4), the imidazoline group will be predominantly protonated, conferring a positive charge on the molecule. This charge is important for its interaction with the binding pockets of adrenergic receptors.

Comprehensive Pharmacology

The clinical effects of phentolamine are a direct manifestation of its interactions at molecular, cellular, and systemic levels. Its pharmacology is defined by its mechanism of action, the resulting pharmacodynamic effects, and the pharmacokinetic profile that governs its concentration over time in the body.

Mechanism of Action

Phentolamine's pharmacological activity is rooted in its ability to interact with several receptor systems, with its primary and most clinically relevant effects mediated through the adrenergic system.

Primary Mechanism: Non-selective Alpha-Adrenergic Antagonism

Phentolamine functions as a competitive and reversible antagonist at both α1- and α2-adrenergic receptors.[1] This non-selectivity is the defining feature of its pharmacology. It binds to these receptors with high affinity, effectively blocking the actions of endogenous catecholamines like norepinephrine and epinephrine. Experimental binding assays have quantified this affinity, reporting a dissociation constant (

Kd​) of 16.6 nM for α1 receptors and an inhibitory constant (Ki​) of 5.0 nM for α2 receptors.[15] The consequences of blocking these two receptor subtypes are distinct and synergistic.

• α1-Receptor Blockade: Alpha-1 adrenergic receptors are Gq-protein coupled receptors located primarily on post-junctional vascular smooth muscle cells. Their activation by catecholamines initiates a signaling cascade involving phospholipase C, which generates the second messengers inositol trisphosphate (IP3​) and diacylglycerol (DAG). This leads to the release of intracellular calcium from the sarcoplasmic reticulum, causing smooth muscle contraction and vasoconstriction. By competitively blocking α1-receptors, phentolamine prevents this cascade, resulting in decreased intracellular calcium, relaxation of vascular smooth muscle, vasodilation, and a subsequent fall in systemic blood pressure.[13] This is the principal mechanism behind its antihypertensive effect. In the eye, this same α1-blockade on the radial iris dilator muscle causes the muscle to relax, leading to miosis (pupil constriction) and the reversal of pharmacologically-induced mydriasis.[5]
• α2-Receptor Blockade: Alpha-2 adrenergic receptors are Gi-protein coupled receptors located primarily on pre-synaptic nerve terminals of sympathetic neurons. They function as autoreceptors, providing a crucial negative feedback mechanism. When norepinephrine is released into the synapse and binds to these presynaptic α2-receptors, it inhibits further norepinephrine release. Phentolamine blocks this inhibitory feedback loop.[2] Consequently, sympathetic nerve firing leads to a greater and more sustained release of norepinephrine into the synaptic cleft, an effect that profoundly influences the drug's overall cardiovascular profile.[2]

Secondary and Ancillary Mechanisms

While α-adrenergic antagonism is its primary action, phentolamine exhibits other pharmacological activities that may contribute to its overall effects.

• Beta-Adrenergic Stimulation: Some evidence suggests that phentolamine may also directly or indirectly stimulate β-adrenergic receptors. This action could contribute to the positive inotropic (increased contractility) and chronotropic (increased heart rate) effects observed on cardiac muscle, as well as to peripheral vasodilation.[2]
• Non-Adrenergic Endothelium-Mediated Relaxation: In studies of penile corpus cavernosum tissue, phentolamine has been shown to induce smooth muscle relaxation through a mechanism independent of adrenergic receptors. This effect is dependent on an intact endothelium and is diminished by inhibitors of nitric oxide synthase (NOS), suggesting that phentolamine can promote vasodilation by stimulating the production of nitric oxide.[16]
• Other Receptor and Channel Interactions: Phentolamine may also block 5-hydroxytryptamine (5-HT) receptors, which could play a minor role in its vasodilatory effects.[3] Additionally, its ability to stimulate insulin secretion has been linked to the blockade of ATP-sensitive potassium channels in pancreatic beta cells.[5]

Pharmacodynamics

The observable clinical effects of phentolamine are the net result of its complex mechanism of action, particularly the interplay between α1- and α2-receptor blockade.

Cardiovascular Effects

The hemodynamic response to phentolamine is a direct and predictable consequence of its dual receptor antagonism. The α1-receptor blockade on vascular smooth muscle causes systemic vasodilation, leading to a decrease in total peripheral resistance and a fall in blood pressure.[3] This hypotension is detected by arterial baroreceptors, which trigger a compensatory reflex increase in sympathetic nervous system outflow to the heart and blood vessels.[2]

This physiological response is dramatically amplified by phentolamine's simultaneous blockade of presynaptic α2-receptors. By removing the normal inhibitory feedback on norepinephrine release, the reflex sympathetic discharge results in an exaggerated release of norepinephrine at the cardiac synapses. This flood of norepinephrine acts on cardiac β1-receptors, causing a much more pronounced reflex tachycardia and an increase in cardiac output than would be seen with a selective α1-blocker.[2] This powerful causal sequence—from non-selective α-blockade to vasodilation, followed by a supercharged baroreceptor reflex—explains both the drug's potent efficacy and its most significant risks. The rapid and profound blood pressure reduction is highly effective in controlling hypertensive crises driven by catecholamine excess, such as in pheochromocytoma.[17] However, the same mechanism is responsible for the severe adverse effects of hypotension, tachycardia, cardiac arrhythmias, and the potential for myocardial ischemia or infarction, which ultimately led to its contraindication in patients with coronary artery disease.[6]

Ocular Effects

In the eye, the pharmacodynamic effect is localized and targeted. Pharmacologically-induced mydriasis (pupil dilation) is often achieved with agents that stimulate the α1-receptors on the radial iris dilator muscle. Phentolamine reverses this effect by blocking these receptors, causing the muscle to relax and leading to a reduction in pupil diameter.[5] When administered as an ophthalmic solution, the onset of this effect occurs within approximately 30 minutes, with a maximal effect observed between 60 and 90 minutes.[5]

Effects on Erectile Tissue

The therapeutic effect of phentolamine in erectile dysfunction is mediated by its local α-adrenergic blockade within the penis. This action causes relaxation of the trabecular cavernous smooth muscles and dilation of the penile arteries.[3] This vasodilation significantly increases arterial blood flow into the corpus cavernosa, leading to engorgement and erection. This effect is further supported by its ability to induce non-adrenergic, nitric oxide-mediated vasodilation.[16]

Pharmacokinetics (ADME)

The absorption, distribution, metabolism, and elimination (ADME) profile of phentolamine is highly dependent on the route of administration. This pharmacokinetic variability is a critical factor that has shaped its evolution from a systemic drug to a locally acting agent. The stark contrast in half-life between intravenous and other routes is not merely a descriptive parameter but a prescriptive one, fundamentally defining the drug's appropriate clinical roles.

Absorption

• Intravenous (IV) and Intramuscular (IM): Administration via these routes leads to rapid systemic availability. The onset of action is nearly immediate with IV injection (1–2 minutes) and rapid with IM injection (15–20 minutes), making these routes ideal for managing acute hypertensive emergencies.[20]
• Submucosal (Dental): When administered as OraVerse for the reversal of dental anesthesia, peak plasma concentrations are achieved locally and systemically within 10 to 20 minutes.[5]
• Oral: Oral bioavailability has been reported to be variable, ranging from 30% to 100%.[13] Following an oral dose of 40 or 80 mg, peak plasma concentrations are reached in approximately 30 to 40 minutes.[21]
• Ophthalmic: After topical administration of Ryzumvi, systemic absorption is minimal. Peak plasma concentrations are very low (median 0.45 ng/mL) and are reached between 15 minutes and one hour post-instillation.[5]

Distribution

Phentolamine is moderately bound to plasma proteins (54%) and exhibits a large apparent volume of distribution (Vd​) of approximately 6 L/kg, which indicates extensive distribution into peripheral tissues.[13] As a lipophilic compound, it is also reported to cross the blood-brain barrier.[5]

Metabolism

Phentolamine undergoes extensive hepatic metabolism, although the specific metabolic pathways have not been fully elucidated in the available literature.[2]

Elimination

The drug is eliminated primarily through the kidneys, with about 80% of a dose excreted via renal pathways and 20% via fecal excretion.[13] However, only a small fraction (approximately 10–13%) of a parenteral dose is excreted in the urine as the unchanged parent drug, underscoring the importance of hepatic metabolism.[3]

The elimination half-life is a key parameter that varies dramatically by route of administration and dictates clinical utility.

• Intravenous: The half-life following IV administration is very short, approximately 19 minutes.[2] This rapid elimination is highly advantageous for managing volatile intraoperative hypertension, as it allows for precise titration and prevents prolonged hypotension after the stimulus (e.g., tumor removal) is gone. Conversely, this same property made it unsuitable for chronic oral hypertension management.
• Submucosal: The terminal elimination half-life after submucosal injection is significantly longer, at approximately 2 to 3 hours.[5] This pharmacokinetic profile was deliberately leveraged in the development of OraVerse to provide a sustained local anesthetic reversal effect without causing prolonged systemic side effects.
• Oral: The half-life after oral administration is approximately 3.32 hours.[22]

Table 2: Summary of Pharmacokinetic Parameters by Route of Administration

Parameter	Intravenous (IV)	Submucosal (Dental)	Oral	Ophthalmic
Onset of Action	1-2 minutes 20	~10-20 minutes 20	30-40 minutes 21	~30 minutes 5
Tmax	Immediate	10-20 minutes 5	30-40 minutes 21	15-60 minutes 5
Elimination Half-life	19 minutes 2	2-3 hours 5	~3.3 hours 22	Not specified (systemic levels low)

Clinical Applications and Efficacy

The therapeutic landscape of phentolamine is diverse, encompassing both well-established, FDA-sanctioned indications and a range of off-label uses driven by its potent alpha-blocking pharmacology.

FDA-Approved Indications

Phentolamine has four distinct indications approved by the U.S. Food and Drug Administration (FDA), reflecting its utility in both critical care and specialized outpatient settings.

Management of Pheochromocytoma

Pheochromocytoma is a neuroendocrine tumor that secretes high levels of catecholamines, leading to severe and often paroxysmal hypertension. Phentolamine is a cornerstone of medical management in this context.

• Diagnosis (Phentolamine Blocking Test): Historically, phentolamine was used as a diagnostic tool. The test involves administering a 5 mg IV or IM dose and monitoring for a significant drop in blood pressure (defined as >35 mmHg systolic and >25 mmHg diastolic), which would be suggestive of catecholamine-dependent hypertension.[23] However, due to the availability of more accurate and safer biochemical assays measuring plasma and urinary catecholamines and their metabolites, this pharmacological test is now largely obsolete and reserved only for select situations where additional confirmation is deemed necessary.[5]
• Prevention and Control of Hypertensive Episodes: This is the primary and critical indication for phentolamine in pheochromocytoma. It is administered parenterally before surgery (1–2 hours preoperatively) and during the surgical procedure to prevent or control severe hypertensive episodes that can be triggered by anesthetic induction, stress, or direct manipulation of the tumor.[5] Its rapid onset and short duration of action make it ideal for titrating blood pressure in this volatile clinical setting.

Prevention and Treatment of Dermal Necrosis from Vasopressor Extravasation

Extravasation—the accidental leakage of intravenously administered drugs into the surrounding tissue—of potent vasoconstrictors like norepinephrine can lead to intense local ischemia, resulting in dermal necrosis and sloughing. Phentolamine serves as a direct antidote. When infiltrated locally into the affected area (typically 5–10 mg diluted in 10 mL of saline), its α-blocking action counteracts the vasoconstriction, restores local blood flow, and prevents tissue damage.[5] For preventative purposes, phentolamine can also be added directly to intravenous solutions containing norepinephrine.[6]

Reversal of Soft-Tissue Anesthesia (OraVerse)

OraVerse is a specific formulation of phentolamine mesylate (0.4 mg/1.7 mL) in a dental cartridge, approved for the reversal of soft-tissue anesthesia (numbness of the lip and tongue) in adults and pediatric patients aged 3 years and older.[28] Local anesthetics used in dentistry are often combined with a vasoconstrictor (like epinephrine) to prolong their duration of action. By administering phentolamine into the same area, its vasodilatory effect increases local blood flow, which accelerates the removal of the anesthetic agent from the tissue and hastens the return of normal sensation and function.[2]

Reversal of Pharmacologically-Induced Mydriasis (Ryzumvi)

Ryzumvi is a 0.75% ophthalmic solution of phentolamine approved for reversing pharmacologically-induced mydriasis (pupil dilation) in adults and children aged 3 years and older.[8] After an ophthalmic examination where dilating drops are used, Ryzumvi can be instilled to rapidly reverse the dilation by blocking α1-receptors on the iris dilator muscle. This reduces photosensitivity and blurred vision, allowing patients to resume normal activities, such as driving or reading, more quickly.[2]

Off-Label and Investigational Uses

Phentolamine's potent pharmacology has led to its use in several clinical scenarios beyond its approved indications.

• Hypertensive Crises from Catecholamine Excess: Phentolamine is effective in managing hypertensive emergencies arising from conditions other than pheochromocytoma, such as those caused by cocaine toxicity, amphetamine overdose, interactions with monoamine oxidase inhibitors (MAOIs), or abrupt clonidine withdrawal.[3] In the specific case of cocaine-induced cardiovascular complications, phentolamine is considered a second-line agent, to be used only after patients have failed to respond adequately to first-line treatments like benzodiazepines and nitroglycerin.[2]
• Erectile Dysfunction (ED): Phentolamine is used off-label via intracavernosal injection, often in a compounded mixture with papaverine and/or alprostadil (known as "Trimix" or "Bimix"), to induce a firm erection by causing direct vasodilation of penile arteries.[3] Oral formulations of phentolamine (e.g., Vasomax) have also been investigated in clinical trials for ED with some success.[21]
• Other Uses: Phentolamine has been employed in the diagnosis and treatment of complex regional pain syndrome (CRPS).[2] It has also been proposed for treating the severe hypertension associated with Irukandji syndrome, a condition caused by the venom of certain jellyfish.[32] Historically, it was used investigationally to reduce cardiac afterload in patients with acute myocardial infarction complicated by left ventricular failure.[25] More recently, a phase 2 clinical trial was completed to evaluate its potential for treating severe night vision disturbances.[33]

Table 3: FDA-Approved and Off-Label Clinical Indications

Indication	Status	Formulation(s) Used	Key Clinical Role
Pheochromocytoma Management	FDA-Approved	Injectable (powder)	Control of hypertensive episodes during surgery
Vasopressor Extravasation	FDA-Approved	Injectable (powder)	Antidote to prevent tissue necrosis
Reversal of Dental Anesthesia	FDA-Approved (OraVerse)	Injectable Solution	Accelerate recovery of soft tissue sensation
Reversal of Mydriasis	FDA-Approved (Ryzumvi)	Ophthalmic Solution	Reverse pupil dilation after eye exams
Hypertensive Crises (non-pheo)	Off-Label	Injectable (powder)	Management of catecholamine excess (e.g., cocaine)
Erectile Dysfunction	Off-Label	Injectable (powder)	Intracavernosal injection to induce erection
Complex Regional Pain Syndrome	Off-Label	Injectable (powder)	Diagnostic and therapeutic roles

Dosage and Administration

Proper dosing and administration of phentolamine are critical for achieving therapeutic efficacy while minimizing the risk of adverse events. The appropriate formulation, dose, and route are highly specific to the clinical indication.

Formulations and Strengths

Phentolamine is available in three distinct formulations:

• Powder for Injection: Supplied as a sterile, lyophilized powder containing 5 mg of phentolamine mesylate per vial, which must be reconstituted with sterile water for injection prior to administration.[26]
• Injectable Solution (OraVerse): A pre-filled 1.7 mL dental cartridge containing 0.4 mg of phentolamine mesylate.[24]
• Ophthalmic Solution (Ryzumvi): A sterile 0.75% solution of phentolamine supplied in single-patient-use vials.[31]

Administration Guidelines

The dosing regimens for phentolamine vary significantly based on the indication and patient population.

Table 4: Dosing Regimens for Key Indications

Indication	Patient Population	Dosage and Administration	Source(s)
Pheochromocytoma (Surgery)	Adults	5 mg IV/IM, 1-2 hours pre-op; repeat as needed during surgery.	6
	Children	1 mg or 0.05-0.1 mg/kg IV/IM; maximum single dose is 5 mg.	6
Extravasation (Treatment)	Adults & Children	5-10 mg (adults) or 0.1-0.2 mg/kg (children, max 10 mg) diluted in 10 mL saline, infiltrated into the affected area within 12 hours.	6
Dental Anesthesia Reversal (OraVerse)	Adults & Children >12y	The dose is equivalent to the number of local anesthetic cartridges used (e.g., 1 cartridge anesthetic → 1 cartridge OraVerse [0.4 mg]). Maximum recommended dose is 2 cartridges (0.8 mg). Administer via the same injection site and technique as the local anesthetic.	23
	Children 6-12y (>30 kg)	Same as adults, but doses greater than 1 cartridge have not been studied.	29
	Children 3-6y (15-30 kg)	The maximum recommended dose is ½ cartridge (0.2 mg). Not recommended for use in children <3 years of age or weighing <15 kg.	28
Mydriasis Reversal (Ryzumvi)	Adults & Children ≥12y	Instill 1 to 2 drops in each affected eye. If 2 drops are used, the second should be administered 5 minutes after the first.	31
	Children 3-11y	Instill 1 drop in each affected eye.	31

Safety Profile and Risk Management

While phentolamine is a valuable therapeutic agent, its potent vasodilatory and cardiac-stimulating effects necessitate a thorough understanding of its safety profile to ensure appropriate patient selection and monitoring.

Adverse Reactions

The adverse effects of phentolamine are largely predictable extensions of its pharmacology, with the most significant risks being cardiovascular in nature.

• Cardiovascular: Acute and prolonged hypotension, orthostatic hypotension, reflex tachycardia, and cardiac arrhythmias are the most prominent adverse effects of systemic administration.[15] These effects are a direct result of its non-selective alpha-blockade. More severe, life-threatening reactions have been reported, including myocardial infarction (MI), cerebrovascular spasm, and cerebrovascular occlusion. These events are typically precipitated by marked hypotensive episodes that lead to a shock-like state and compromised perfusion of the heart and brain.[6]
• Neurological: Common central nervous system side effects include dizziness, weakness, and headache.[15]
• Gastrointestinal: Nausea, vomiting, diarrhea, and abdominal pain may occur. Phentolamine can also stimulate gastric smooth muscle and may aggravate pre-existing peptic ulcers.[18]
• Other Systemic Effects: Nasal congestion (stuffiness) and cutaneous flushing are common and are caused by the vasodilation of mucosal and dermal blood vessels, respectively.[15]
• Route-Specific Effects:
• Intracavernosal Injection: When used for erectile dysfunction, priapism (a prolonged, painful erection lasting more than 4 hours) is a rare but serious medical emergency that can lead to permanent tissue damage if not treated promptly. More common local effects include pain at the injection site, penile bruising (ecchymosis), and the formation of fibrotic nodules.[19]
• Ophthalmic Administration (Ryzumvi): The most frequently reported adverse reactions are local and transient. These include instillation site discomfort (stinging, pain, burning), conjunctival hyperemia (redness), and dysgeusia (an altered or metallic taste sensation).[31]

Contraindications, Warnings, and Precautions

Strict adherence to contraindications and warnings is essential for the safe use of phentolamine.

• Absolute Contraindications: Phentolamine is contraindicated in patients with a known hypersensitivity to the drug or its components. Crucially, it is also contraindicated in patients with a history of myocardial infarction, coronary insufficiency, angina, or any other evidence of coronary artery disease.[6] The drug's potential to cause hypotension and reflex tachycardia can increase myocardial oxygen demand and decrease coronary perfusion, which can be dangerous in these patients.
• Warnings and Precautions:
• Cardiovascular Risk: Due to the risk of inducing severe hypotension leading to shock-like states, MI, or stroke, phentolamine must be used with extreme caution in any patient with a history of cardiovascular or cerebrovascular disease.[6] Continuous monitoring of blood pressure and heart rate is essential during parenteral administration.
• Pregnancy: Phentolamine is designated as Pregnancy Category C. Animal reproduction studies at high oral doses showed evidence of slightly decreased fetal growth and skeletal immaturity. There are no adequate and well-controlled studies in pregnant women. Therefore, phentolamine should be used during pregnancy only if the potential benefit clearly justifies the potential risk to the fetus.[6] It is important to note, however, that the effective diagnosis and treatment of pheochromocytoma during pregnancy are critical for favorable maternal and fetal outcomes.[20]
• Lactation: It is not known whether phentolamine is excreted in human milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the medication to the mother.[6]

Management of Overdosage

Overdosage with phentolamine is a medical emergency that requires immediate and supportive intervention.

• Signs and Symptoms: The clinical presentation of overdose is dominated by severe cardiovascular disturbances, including profound hypotension, shock, marked tachycardia, and cardiac arrhythmias. Other possible signs include central nervous system excitation, headache, sweating, nausea, vomiting, diarrhea, and hypoglycemia.[5]
• Treatment: There is no specific antidote for phentolamine overdose. Treatment is entirely supportive and aimed at managing the cardiovascular collapse. The patient should be placed in a supine position with legs elevated. Intravenous administration of a plasma expander should be initiated to restore intravascular volume. If a vasopressor is required to treat severe hypotension, norepinephrine is the agent of choice.

It is critically important that epinephrine should not be used to treat phentolamine-induced hypotension.[6] This is due to a phenomenon known as "epinephrine reversal." Epinephrine possesses both α1-agonist (vasoconstrictor) and β2-agonist (vasodilator) properties. In the presence of phentolamine, the α1-receptors are blocked, leaving the β2-mediated vasodilatory effects of epinephrine unopposed. Administering epinephrine in this setting will lead to a paradoxical and potentially catastrophic further decrease in blood pressure. Norepinephrine, which has potent α-agonist activity and minimal β2-agonist activity, can effectively overcome the competitive blockade at α1-receptors and restore blood pressure.

Drug and Disease Interactions

The clinical use of phentolamine requires careful consideration of potential interactions with other medications and co-existing disease states, which can significantly alter its efficacy and safety profile.

Drug Interactions

Phentolamine is subject to numerous drug interactions, primarily pharmacodynamic in nature, that can lead to exaggerated hypotensive effects.

• Pharmacodynamic Synergism (Hypotension):
• Phosphodiesterase-5 (PDE5) Inhibitors: Co-administration with drugs like sildenafil, tadalafil, and vardenafil is particularly hazardous. Both phentolamine and PDE5 inhibitors are potent vasodilators, and their combined use can lead to severe, synergistic hypotension. This interaction is considered serious, and combination use is generally contraindicated or requires extreme caution with dose reduction and separation.[19]
• Other Antihypertensive Agents: The hypotensive effects of phentolamine are additive with those of other antihypertensive drugs, including beta-blockers, calcium channel blockers, ACE inhibitors, and other vasodilators. Close blood pressure monitoring is required when these agents are used concomitantly.[19]
• Other Alpha-1 Blockers: Co-administration with other α1-blockers, such as tamsulosin or alfuzosin, will result in additive vasodilatory effects and an increased risk of severe hypotension and orthostasis.[19]
• Ethanol: Alcohol can potentiate the hypotensive effects of phentolamine and should be avoided.[36]
• Pharmacodynamic Antagonism:
• Alpha-Adrenergic Agonists: Phentolamine directly antagonizes the vasoconstrictor effects of α-agonists like phenylephrine and norepinephrine. This antagonistic relationship forms the basis of its therapeutic use as an antidote for vasopressor extravasation.[41]
• Other Significant Interactions:
• Lofexidine and Yohimbe: These drugs have complex interactions with α2-adrenergic receptors and are associated with serious interactions when combined with phentolamine, potentially leading to unpredictable and severe hemodynamic changes.[24]

Table 5: Clinically Significant Drug Interactions

Interacting Drug/Class	Severity	Mechanism/Effect	Management Recommendation	Source(s)
PDE5 Inhibitors (sildenafil, vardenafil)	Serious/Contraindicated	Pharmacodynamic synergism; severe hypotension.	Avoid or use with extreme caution at lowest doses, separated in time.	19
Other Alpha-1 Blockers (tamsulosin)	Serious	Additive vasodilation; severe hypotension.	Avoid or Use Alternate Drug.	24
Epinephrine (in overdose context)	Contraindicated	"Epinephrine Reversal" - unopposed β2 vasodilation causes paradoxical hypotension.	Use norepinephrine instead.	6
Beta-Blockers	Moderate	Additive antihypertensive effects.	Monitor BP closely.	19
Other Antihypertensives	Moderate	Additive antihypertensive effects.	Monitor BP closely.	20
Alpha-Adrenergic Agonists	N/A (Antagonism)	Phentolamine blocks the pressor effects of agonists.	This is the therapeutic basis for some uses.	41

Disease State Interactions

Certain pre-existing medical conditions can substantially increase the risks associated with phentolamine therapy.

• Cardiovascular Dysfunction: This represents a major interaction. As previously noted, phentolamine is contraindicated in patients with a history of myocardial infarction or coronary artery disease. The drug-induced hypotension and reflex tachycardia can precipitate myocardial ischemia in susceptible individuals.[42]
• Cerebrovascular Disorders: This is a moderate potential interaction. In patients with a history of cerebrovascular disease, the marked hypotensive episodes that can occur with phentolamine therapy may lead to reduced cerebral perfusion, potentially causing cerebrovascular spasm or occlusion. Cautious use is warranted in this population.[42]
• Hepatic and Renal Dysfunction: Phentolamine is extensively metabolized by the liver and its metabolites are excreted by the kidneys. While specific dose adjustments have not been established, therapy should be administered cautiously in patients with severe hepatic or renal impairment due to the potential for altered drug clearance and accumulation.[42]

Regulatory History and Current Status

The regulatory and commercial history of phentolamine reflects its clinical evolution from a broad-spectrum systemic agent to a highly specialized, locally acting drug.

Initial Approval and Evolution

Phentolamine was first approved by the FDA in 1952 under the brand name Regitine (NDA 8-278). Its initial indications were for the diagnosis and perioperative management of pheochromocytoma and for preventing dermal necrosis from norepinephrine extravasation.[43] Although its potential as a general oral antihypertensive was explored, this use was ultimately abandoned due to the unfavorable adverse effect profile associated with the chronic systemic alpha-blockade required for long-term blood pressure control.[1]

Discontinuation and Shortages

In 2000, the original manufacturer, Novartis (formerly Ciba), discontinued marketing Regitine in the United States, although a generic version remained available.[10] Over the years, the generic injectable form of phentolamine has been subject to periods of national drug shortages. These shortages have highlighted its critical, and often irreplaceable, role as the standard-of-care antidote for vasopressor extravasation, prompting reviews of alternative treatment strategies.[10]

Modern Repurposing and New Approvals

The 21st century has marked a renaissance for phentolamine, driven by innovative pharmaceutical development that repurposed the molecule for targeted, low-dose applications, thereby maximizing local efficacy while minimizing systemic risk. This strategy led to two new FDA approvals for distinct formulations:

• OraVerse (phentolamine mesylate) Injection: Developed by Novalar Pharmaceuticals, OraVerse was approved by the FDA on May 9, 2008. This approval created a new therapeutic category for the reversal of local soft-tissue anesthesia in dentistry, addressing a previously unmet clinical need.[30]
• Ryzumvi (phentolamine mesylate) Ophthalmic Solution: Developed by Ocuphire Pharma, Ryzumvi was approved by the FDA on September 25, 2023. This approval introduced the first pharmacological agent specifically designed for the reversal of pharmacologically-induced mydriasis, offering a significant convenience for patients undergoing dilated eye examinations.[8]

Current Status

Today, phentolamine holds a unique position in medicine. The generic injectable formulation remains a vital, albeit niche, medication in the critical care and surgical settings for managing pheochromocytoma and treating vasopressor extravasation. Simultaneously, the branded, low-dose local formulations, OraVerse and Ryzumvi, have expanded its use into routine outpatient dental and ophthalmic care. The journey of phentolamine from a systemic drug with limited long-term utility to a portfolio of highly specialized agents exemplifies a successful strategy in modern pharmacology: leveraging a deep understanding of a molecule's mechanism to identify novel indications and develop innovative delivery systems that optimize the therapeutic index.

Works cited

1. Phentolamine | C17H19N3O | CID 5775 - PubChem, accessed August 25, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Phentolamine
2. Phentolamine - Wikipedia, accessed August 25, 2025, https://en.wikipedia.org/wiki/Phentolamine
3. Phentolamine CAS#: 50-60-2 - ChemicalBook, accessed August 25, 2025, https://m.chemicalbook.com/ProductChemicalPropertiesCB6665216_EN.htm
4. Phentolamine mesylate | DrugBank Online, accessed August 25, 2025, https://go.drugbank.com/salts/DBSALT000980
5. Phentolamine: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 25, 2025, https://go.drugbank.com/drugs/DB00692
6. Phentolamine: Package Insert / Prescribing Information - Drugs.com, accessed August 25, 2025, https://www.drugs.com/pro/phentolamine.html
7. Phentolamine - brand name list from Drugs.com, accessed August 25, 2025, https://www.drugs.com/ingredient/phentolamine.html
8. Ryzumvi (phentolamine mesylate) FDA Approval History - Drugs.com, accessed August 25, 2025, https://www.drugs.com/history/ryzumvi.html
9. Phentolamine (Systemic - Memorial Sloan Kettering Cancer Center, accessed August 25, 2025, https://www.mskcc.org/cancer-care/patient-education/medications/adult/phentolamine-systemic
10. Drug Shortage Detail: Phentolamine Mesylate for Injection - ASHP, accessed August 25, 2025, https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id=191
11. Phentolamine | ≥99%(HPLC) | In Stock | Others - Selleck Chemicals, accessed August 25, 2025, https://www.selleckchem.com/products/phentolamine.html
12. Phentolamine | 50-60-2 | FP37047 - Biosynth, accessed August 25, 2025, https://www.biosynth.com/p/FP37047/50-60-2-phentolamine
13. Phentolamine | Deranged Physiology, accessed August 25, 2025, https://derangedphysiology.com/main/pharmacopeia/phentolamine
14. go.drugbank.com, accessed August 25, 2025, https://go.drugbank.com/drugs/DB00692#:~:text=Phentolamine%20is%20a%20reversible%2C%20competitive,and%20alpha%2D2%20adrenergic%20receptors.&text=It%20causes%20vasodilation%20of%20vascular%20smooth%20muscles.&text=Pupil%20dilation%20is%20primarily%20controlled,the%20alpha%2D1%20adrenergic%20receptors.
15. PHENTOLAMINE - Inxight Drugs, accessed August 25, 2025, https://drugs.ncats.io/drug/Z468598HBV
16. Phentolamine mesylate relaxes penile corpus cavernosum tissue by adrenergic and non ... - PubMed, accessed August 25, 2025, https://pubmed.ncbi.nlm.nih.gov/9884917/
17. What is the use of Phentolamine (Regitine)? - Dr.Oracle AI, accessed August 25, 2025, https://www.droracle.ai/articles/87025/phentolamine
18. Phentolamine | Davis's Drug Guide for Rehabilitation Professionals, accessed August 25, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873%C2%A7ionid=139022310
19. Phentolamine (injection route) - Side effects & dosage - Mayo Clinic, accessed August 25, 2025, https://www.mayoclinic.org/drugs-supplements/phentolamine-injection-route/description/drg-20065481
20. Phentolamine (Systemic) | Drug Lookup | Pediatric Care Online - AAP Publications, accessed August 25, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/8986/Phentolamine-Systemic
21. Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction - PubMed, accessed August 25, 2025, https://pubmed.ncbi.nlm.nih.gov/10845768/
22. PHENTOLAMINE HYDROCHLORIDE - Inxight Drugs, accessed August 25, 2025, https://drugs.ncats.io/substance/86DRW83R1H
23. Phentolamine Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 25, 2025, https://www.drugs.com/dosage/phentolamine.html
24. Regitine, OraVerse (phentolamine) dosing, indications, interactions, adverse effects, and more - Medscape Reference, accessed August 25, 2025, https://reference.medscape.com/drug/regitine-oraverse-phentolamine-342392
25. Phentolamine Monograph for Professionals - Drugs.com, accessed August 25, 2025, https://www.drugs.com/monograph/phentolamine.html
26. PHENTOLAMINE MESYLATE FOR INJECTION, USP - DailyMed, accessed August 25, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=ed6c506c-5535-4b7c-ae1a-d63f09d796c9
27. Alternative Pharmacological Management of Vasopressor Extravasation in the Absence of Phentolamine - PMC - PubMed Central, accessed August 25, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5565133/
28. OraVerse™ - accessdata.fda.gov, accessed August 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022159s011lbl.pdf
29. center for drug evaluation and - eCopy, Inc. - FDA, accessed August 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022159s000_Lbl.pdf
30. OraVerse (phentolamine mesylate) FDA Approval History - Drugs.com, accessed August 25, 2025, https://www.drugs.com/history/oraverse.html
31. NDA 217064 Page 4 | FDA, accessed August 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217064s000lbl.pdf
32. Phentolamine | StatPearls | Treatment & Management, accessed August 25, 2025, https://www.statpearls.com/point-of-care/search?q=Phentolamine
33. Phentolamine Completed Phase 2 Trials for Disturbance; Vision, Loss / Decrease in Night Vision Treatment | DrugBank Online, accessed August 25, 2025, https://go.drugbank.com/drugs/DB00692/clinical_trials?conditions=DBCOND0121499%2CDBCOND0121500&phase=2&purpose=treatment&status=completed
34. Phentolamine - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Lactation, Pregnanacy | Drug Index | Pediatric Oncall, accessed August 25, 2025, https://www.pediatriconcall.com/drugs/phentolamine/1248
35. ff65fd62-d66a-48f3-bd95-2870b8cf74cf.xml - accessdata.fda.gov, accessed August 25, 2025, https://www.accessdata.fda.gov/spl/data/ff65fd62-d66a-48f3-bd95-2870b8cf74cf/ff65fd62-d66a-48f3-bd95-2870b8cf74cf.xml
36. Phentolamine: Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 25, 2025, https://www.rxlist.com/phentolamine/generic-drug.htm
37. fadavispt.mhmedical.com, accessed August 25, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873%C2%A7ionid=139022310#:~:text=Adverse%20Reactions%2FSide&text=EENT%3A%20nasal%20stuffiness.,Derm%3A%20flushing.
38. What are the side effects of phentolamine? | ClinicalKeyAI - Elsevier, accessed August 25, 2025, https://www.elsevier.com/resources/clinicalkey-ai/what-are-the-side-effects-of-phentolamine-751c
39. What are the side effects of Phentolamine Mesylate? - Patsnap Synapse, accessed August 25, 2025, https://synapse.patsnap.com/article/what-are-the-side-effects-of-phentolamine-mesylate
40. Phentolamine Mesylate for Injection - RxList, accessed August 25, 2025, https://www.rxlist.com/phentolamine-mesylate-for-injection-drug.htm
41. Showing BioInteractions for Phentolamine (DB00692) | DrugBank Online, accessed August 25, 2025, https://go.drugbank.com/drugs/DB00692/biointeractions
42. Phentolamine Disease Interactions - Drugs.com, accessed August 25, 2025, https://www.drugs.com/disease-interactions/phentolamine.html
43. Phentolamine Clinpharm Pediatric Review - FDA, accessed August 25, 2025, https://www.fda.gov/media/71684/download
44. Summary Review for Regulatory Action - accessdata.fda.gov, accessed August 25, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/summary_review/2008/022159s000_SUMR.pdf
45. phentolamine - Drug Central, accessed August 25, 2025, https://drugcentral.org/drugcard/2142